Immunobiology and pathophysiology of heparin-induced thrombocytopenia/thrombosis syndrome - An update

Turkish Journal of Haematology

Volumn 19, Issue 2, 2002, Pages 127-131

  Ahmad, Sarfraz ^a   Iqbal, Omer ^a   Tobu, Mahmut ^a   Demir, Muzaffer ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Antiheparin PF IV antibodies; Antithrombin drugs; Autoimmune disorder; Heparin induced thrombocytopenia (HIT); Pathophysiology of HIT; Platelet activation

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CD32 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; GLYCOSAMINOGLYCAN; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVIPARIN; THROMBOCYTE ANTIBODY; THROMBOCYTE FACTOR 4; THROMBOPLASTIN;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG INDUCED DISEASE; GENETIC HETEROGENEITY; HEMOSTASIS; HUMAN; IMMUNOBIOLOGY; LUNG EMBOLISM; PATHOGENESIS; PATHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0036399248     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Fahey VA. Heparin-induced thrombocytopenia. J Vasc Nurs 1995;13:112.
2. Chong BH. Heparin-induced thrombocytopenia. Aust N Z J Med 1992;22:145.
3. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 2001;119:64A.
4. Warkentin TE, Kelton JG. A 14 year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502.
5. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;17:257.
6. Creager MA, Beckman JA. Assessment of arterial and venous thrombosis. In: Loscalzo J, Schafer A, (eds). Thrombosis and Hemorrhage. Balitimore: Williams & Wilkins, 1998:491.
7. Ramos RS, Salem BL, Haikal, et al. Critical role of pulmonary angiography in the diagnosis of pulmonary emboli following cardiac surgery. Cath Cardiovasc Dis 1995;36:112.
8. Amiral J, Wolf M, Fischer A, et al. Pathogenicity of IgA and/or IgM antibodies to UFH-PF IV complexes with UFH-induced thrombocytopenia. Br J Haematol 1996;92:954.
9. Fareed J, Walenga JM, Hoppensteadt DA, et al. Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation. Semin Thromb Hemost 1999;25(Suppl 1):37.
10. Fabris F, Ahmad S, Cella G, et al. Pathophysiology of heparin-induced thrombocytopenia: Clinical and diagnostic implications - a review. Arch Pathol Lab Med 2000;124:1657.
11. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost 1998;79:1.
12. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor IV complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia. Thromb Haemost 1992;68:95.
13. Amiral J, Marfaing-Koka A, Poncz M, et al. The biological basis of immune heparin-induced thrombocytopenia. Platelets 1998;9:77.
14. Brandt E, Flad HD. Structure and function of platelet-derived cytokines of the β-thromboglobulin/interleukin 8 family. Platelets 1992;3:295.
15. Nieduszynski I. General physical properties of heparin. In: Lane DA, Lindhahl U (eds). Heparin-Chemical and Biological Properties, Clinical Applications. Boca Raton: CRC Press Inc, 1989:51.
16. Bock PE, Luscombe M, Marshall SE, et al. The multiple complexes formed by the interaction of platelet factor IV with heparin. Biochem J 1980;191:769.
17. Ahmad S, Walenga JM, Jeske WP, et al. Functional heterogeneity of antiheparin-platelet factor IV antibodies: Implications in the pathogenesis of HIT syndrome. Clin Appl Thromb Hemost 1999;5(Suppl 1):32A.
18. Ahmad S, Walenga JM, Jeske WP, et al. Lack of thrombocytopenic response after low molecular weight heparins usage is due to the generation of non-functional antiheparin-platelet factor IV antibodies. J Am Coll Cardiol 2000;35(Suppl A):316A.
19. Herbert J-M, Savi P, Jeske WP, et al. Effect of SR121566A, a potent GPIIb/IIIa antagonist on the HIT serum-induced platelet mediated activation of human endothelial cells. Thromb Haemost 1998;80:326.
20. Blank M, Shoenfeld Y, Tavor S, et al. Antiplatelet factor IV/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002;14:121.
21. Hughes M, Hayward CPM, Warkentin TE, et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000;96:188.
22. Walenga JM, Lewis BE, Hoppensteadt DA, et al. Management of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis syndrome. Clin Appl Thromb Hemost 1997;3(Suppl 1):53A.
23. Breddin HK, Hach-Wunderle V, Nakov, et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001;344:626.
24. Ahmad S, Haas S, Hoppensteadt DA, et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor IV antibodies. Thromb Res 2002; in press.
25. Ahmad S, Lietz H, Daud AN, et al. Upregulation of tissue factor pathway inhibitor by a low-molecular-weight heparin, clivarin, is associated with decreased prevalence of antiheparin-PF IV antibodies: Diagnostic and therapeutic implications. Int Angiol 2001;20(Suppl 1):42A.
26. Untch B, Ahmad S, Jeske WP, et al. Prevalence, isotype, and functionality of anti-heparin-platelet factor IV antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia: The pathogenic role of IgG. Thromb Res 2002;105:17.
27. Lindhoff-Last E, Gerdsen F, Achermann H, et al. Determination of heparin-platelet factor IV-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001;113:886.
28. Ahmad S. Endogenous factors contributing to the generation of heparin-PF IV antibodies. Presentation at the 47th Annual Scientific & Standardization Subcommittee (SSC) Session on "Control of Anticoagulation-Part II" of the ISTH, July 7, 2001, Paris, France.